Teva UK Limited has today launched Lonquex® (lipegfilgrastim) in the UK. Lonquex® is indicated for the reduction of the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
Lonquex® is a new long-acting recombinant granulocyte colony-stimulating factor (G-CSF) with the active ingredient lipegfilgrastim – a novel glycoPEGylated (PEG; polyethylene glycol) filgrastim molecule. Lonquex® is intended as a once per cycle fixed dose, subcutaneous injection for neutrophil support in cancer patients receiving myelosuppresive chemotherapy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
The UK launch is part of a Europe-wide market launch of the medicine, and it has already been launched in several European markets, including Germany, the Netherlands and Ireland.
Read more: PR Newswire